GlassScriptPhysician profile
Natalia B Videva
NPI 1962906586
$5,625.29
in general payments reported to CMS, 2019-2025
33 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,145 · 2022: $2,391 · 2023: $1,105 · 2024: $600 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,046 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.92 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,533.51 | 2021-2024 | Minimed 780g |
| Janssen Pharmaceuticals, INC | $504.26 | 2022-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Astrazeneca Pharmaceuticals LP | $345.63 | 2021-2022 | |
| Alkermes, INC. | $311.03 | 2021-2024 | Aristada, Lybalvi |
| Mannkind Corporation | $310.68 | 2021-2025 | Afrezza |
| Abbott Laboratories | $271.76 | 2021-2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $251.56 | 2021-2025 | Mounjaro, Zepbound |
| Neurocrine Biosciences, INC. | $215.24 | 2021-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $205.38 | 2021-2023 | Abilify Mycite |
| Novo Nordisk INC | $186.03 | 2021-2024 | Rybelsus, Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $174.95 | 2021-2024 | Caplyta |
| Abbvie INC. | $167.19 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.40 | 2021-2025 | Jardiance |
| Lundbeck LLC | $149.85 | 2021-2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $135.71 | 2022-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $108.53 | 2021-2025 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $103.89 | 2021 | |
| Xeris Pharmaceuticals, INC. | $101.21 | 2022-2023 | Gvoke Hypopen, Recorlev |
| Kyowa Kirin, INC. | $59.29 | 2023 | Crysvita |
| Teva Pharmaceuticals USA, INC. | $54.22 | 2022 | |
| Alfasigma USA, INC. | $42.03 | 2021 | |
| Corium, LLC | $35.10 | 2024 | Azstarys |
| Indivior INC. | $28.69 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.04 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.92 | 2023 | |
| Alexion Pharmaceuticals, INC. | $19.11 | 2022 | |
| Horizon Therapeutics Plc | $18.44 | 2021 | |
| Avanir Pharmaceuticals, INC. | $16.93 | 2022 | |
| Almatica Pharma LLC | $16.26 | 2024 | Loreev Xr |
| Adlon Therapeutics L.P. | $14.36 | 2021 | |
| Amryt Pharma Holdings LTD | $14.13 | 2023 | Mycapssa |
| Idorsia Pharmaceuticals US INC | $13.68 | 2023 | Quviviq |
| Athena Bioscience, LLC | $13.28 | 2023 | Nexiclon Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalia Videva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.